<SEC-DOCUMENT>0001193125-15-274836.txt : 20150817
<SEC-HEADER>0001193125-15-274836.hdr.sgml : 20150817
<ACCEPTANCE-DATETIME>20150803161234
ACCESSION NUMBER:		0001193125-15-274836
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150803
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150803
DATE AS OF CHANGE:		20150803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INTEGRA LIFESCIENCES HOLDINGS CORP
		CENTRAL INDEX KEY:			0000917520
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				510317849
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26224
		FILM NUMBER:		151022501

	BUSINESS ADDRESS:	
		STREET 1:		311 ENTERPRISE DRIVE
		CITY:			PLAINSBORO
		STATE:			NJ
		ZIP:			08536
		BUSINESS PHONE:		6092750500

	MAIL ADDRESS:	
		STREET 1:		311 ENTERPRISE DRIVE
		CITY:			PLAINSBORO
		STATE:			NJ
		ZIP:			08536

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTEGRA LIFESCIENCES CORP
		DATE OF NAME CHANGE:	19950614
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d44324d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): August&nbsp;3, 2015 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>INTEGRA LIFESCIENCES HOLDINGS CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of Registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>0-26224</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>51-0317849</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>311 Enterprise Drive </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plainsboro, NJ 08536 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (609)&nbsp;275-0500 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;3, 2015, Integra LifeSciences Holdings Corporation (the
&#147;Company&#148;) announced the commencement of an underwritten public offering of $200,000,000 of shares of its common stock. The Company expects to grant the underwriters of the offering an option to purchase up to $30,000,000 of additional
shares of its common stock. A copy of the press release is attached as Exhibit 99.1 to this report, and is incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 FINANCIAL STATEMENTS AND EXHIBITS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d)
Exhibits </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">99.1</TD>
<TD ALIGN="left" VALIGN="top">Press Release, dated August&nbsp;3, 2015, issued by Integra LifeSciences Holdings Corporation. </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">INTEGRA LIFESCIENCES HOLDINGS CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: August&nbsp;3, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Glenn G. Coleman</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Glenn G. Coleman</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Corporate Vice President and Chief Financial Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated August 3, 2015, issued by Integra LifeSciences Holdings Corporation.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d44324dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g44324ex99_1logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;3, 2015 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Integra LifeSciences Announces Proposed Public Offering of Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLAINSBORO, N.J., Aug. 3, 2015 (GLOBE NEWSWIRE) &#151; Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it intends to offer,
subject to market conditions and other factors, $200,000,000 of its common stock in an underwritten public offering registered under the Securities Act of 1933, as amended. In connection with the offering, Integra expects to grant the underwriters a
30-day option to purchase an additional $30,000,000 of its common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Integra intends to use the net proceeds from the offering, including any net
proceeds received from an exercise of the underwriters&#146; option to purchase additional shares, to reduce outstanding borrowings under Integra&#146;s senior credit facility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares will be issued pursuant to an effective shelf registration statement on Form S-3. Before investing in the offering, interested parties should read
the prospectus for such offering and the other documents Integra has filed with the Securities and Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan, Wells Fargo
Securities and RBC Capital Markets are acting as joint book-running managers for the offering. The offering is being made by means of a prospectus and related prospectus supplement, copies of which may be obtained, when available, from J.P. Morgan
Securities, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by calling (866)&nbsp;803-9204, from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York
10152, by calling (800)&nbsp;326-5897 or by emailing <U>cmclientsupport@wellsfargo.com</U>, or from RBC Capital Markets, LLC, 200 Vesey Street, 8th Floor, New York, NY 10281-8098; Attention: Equity Syndicate; Phone: 877-822-4089; Email:
equityprospectus@rbccm.com. Electronic copies of the prospectus and related prospectus supplement may be obtained by visiting EDGAR on the SEC&#146;s website at <U>http://www.sec.gov</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there
be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state or any jurisdiction. Any offer, if at all, will
be made only by means of a prospectus and related prospectus supplement forming a part of the effective shelf registration statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Integra
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for caregivers, so they can concentrate on providing
the best patient care. Integra offers innovative solutions, including regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit <U>www.integralife.com</U>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements include Integra&#146;s intention to conduct the offering and its intended use of proceeds from the offering. These forward-looking statements are subject to a number of risks, uncertainties and
assumptions about Integra&#146;s business. Integra&#146;s actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including but not limited to those set forth under the heading
&#147;Risk Factors&#148; in Integra&#146;s filings with the Securities and Exchange Commission, including Integra&#146;s Annual Report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Integra undertakes no obligation to
publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You can identify these forward-looking statements by forward-looking words such as &#147;believe,&#148; &#147;may,&#148;
&#147;could,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;seek,&#148; &#147;plan,&#148; &#147;expect,&#148; &#147;should,&#148; &#147;would&#148; and similar expressions in
this press release. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONTACT: Michael Beauleiu </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(609)&nbsp;750-2827 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">michael.beaulieu@integralife.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Angela Steinway </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(609)&nbsp;936-2268 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>angela.steinway@integralife.com </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g44324ex99_1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g44324ex99_1logo.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 2 ## P$1  (1 0,1 ?_$ +D  0 " 04! 0
M       )"@@!! 4&!P(# 0$  @$% 0$              0(#! 4&!P@)"A
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MUTD&M&0"Z #6C$ 57Z:E64C7BOLWX!RW@XP3]I;E2[C71 1, '%LR1LQ"]!
MHF[J_P!-_P![KKMWHA>_*\]BAKA<6TL?L D_T+NSZ?[\6?46* FGS-K-'XT
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M^1#B1A&*R9><>0.3J!$0,H]J$U(,3M3R60[0U/*$CV[UHT=/4T4RE RG7M*
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M?]F3]T_<KP'C&0<MN!G&M!XW<-'*=(>@JW=(J-W"1AM-@$ 415*10@B40'J
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MIEWMG*]VO+_;V[3*\1S/UM#Q+  X Y$!SA7T$JSC[*7_ $D_^ O^C7/U]/\
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M9X5FSJRYRY!6CDNWK55D;)D?+DXV1QB_FG4%"R<M+VU\U339V,KF57CFK@Q
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MUN89I'PEL;VDT+JT&=/=7S#V3Z%.KVV[[9[G/>\?,%O>0RN#;BZ+BV.5KW
6V0!-&F@) KVC-6OM=BKZTIHB:(O_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
